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Abstract
Objective: We studied the annual change in measures of motor, oculomotor and cognitive function in progressive
supranuclear palsy. This had twin objectives, to assess the potential for clinical parameters to monitor disease
progression in clinical trials and to illuminate the progression of pathophysiology.
Methods: Twenty three patients with progressive supranuclear palsy (Richardson’s syndrome) were compared to 22
matched controls at baseline and 16 of these patients compared at baseline and one year using: the progressive
supranuclear palsy rating scale; the unified Parkinson’s disease rating scale; the revised Addenbrooke’s cognitive
examination; the frontal assessment battery; the cubes section of the visual object and space perception battery; the
Hayling and Brixton executive tests; and saccadic latencies.
Results: Patients were significantly impaired in all domains at baseline. However, cognitive performance was
maintained over a year on the majority of tests. The unified Parkinson’s disease rating scale, saccadic latency and
progressive supranuclear palsy rating scale deteriorated over a year, with the latter showing the largest change.
Power estimates indicate that using the progressive supranuclear palsy rating scale as an outcome measure in a
clinical trial would require 45 patients per arm, to identify a 50% reduction in rate of decline with 80% power.
Conclusions: Motor, oculomotor and cognitive domains deteriorate at different rates in progressive supranuclear
palsy. This may be due to differential degeneration of their respective cortical-subcortical circuits, and has major
implications for the selection of outcome measures in clinical trials due to wide variation in sensitivity to annual rates
of decline.
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Introduction
In 1964 Drs Steele, Richardson and Olszewski published
their seminal report of 9 patients “who displayed an unusual
progressive neurological disorder with ocular, motor and
mental features” [1], a condition now known as progressive
supranuclear palsy (PSP) or Richardson’s syndrome.
Subsequent work has sought to understand the natural history
of the disease, including increased awareness of cognitive
decline. With the advent of clinical trials of potential disease
modifying drugs, many based on interfering with the
hyperphosphorylation and aggregation of Tau protein, there is
renewed interest in identifying reliable clinical markers of
disease for early diagnosis and disease progression.
However, tests which are sensitive to the presence of the
disease, may not be optimal for monitoring progression and
vice versa [2]. Some investigators have proposed brain
imaging as a biomarker [3,4]. Others have focussed on the
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clinical progression of PSP, either as part of a composite test
such as the PSP rating scale [4–6], or with separate systems
as summarised in Table 1. Some domains, such as motor
ability, have been studied longitudinally using validated scales
[7]. However, few studies have investigated the longitudinal
change in other domains such as cognition. Predicting PSP tau
pathology is possible with a high degree of accuracy in the
presence of a typical PSP-RS (Richardson’s syndrome)
phenotype [7], but without data detailing progression of disease
in multiple domains, improvements in the rate of decline of
patients in trials could be missed.
In this study, our aim was to assess the rate of decline of
neuropsychological, motor and oculomotor functions. Our
hypothesis was that these functions would all be abnormal at
the time of diagnosis, but that they would deteriorate
differentially. This comparison is not only relevant to our ability
to study disease progression in the context of disease
modifying treatments: it would also offer new insights into the
pathophysiological progression of PSP.
Subjects and Methods
Ethics Statement
The Cambridgeshire research ethics committee approved
this study, including the information sheet, consent documents
and all tests to be carried out. All investigations were carried
out with the adequate understanding and written consent of the
participants involved in the research. The capacity of all
patients was assessed by trained medical staff including a
consultant neurologist. No patient was recruited to this study if
they did not have the capacity to consent. Capacity was
assessed and consent was obtained again after any interval in
testing greater than six weeks. The patients’ family was
included in the process at each stage and, although not
necessary, their agreement to testing was also obtained.
Participants
Twenty-three patients were recruited prospectively from a
specialist neurological clinic for patients with PSP and related
disorders, at Addenbrooke’s hospital between 2007 and 2009.
Contemporary clinical diagnoses for possible or probable PSP
were made by an experienced neurologist according to
consensus criteria [8]. With subsequent information the
diagnoses have been revised to probable or definite PSP as, to
date, ten of the patients have undergone post mortem
examination: all ten had PSP. The phenotype identified by our
inclusion criteria corresponds closely to the PSP-RS
‘Richardson’s syndrome’ rather than other clinical
manifestations of PSP pathology such as PSP-P. Baseline
assessment was carried out at recruitment with interval testing
as close to a year after baseline assessment as practicable.
At baseline, one patient (A) was unable to complete the
saccadometry, two patients (B and C) with poor visual acuity
undertook a non-visual subset of tests only, and two patients
(D and E) failed to complete all of the neuropsychological tests
due to fatigue or intercurrent illness. At interval testing, patient
A was unable to complete the saccadometry but was able to
complete all other tests, patients B, C and D were unable to
complete testing due to intercurrent illness or fatigue and
patient E died before the planned interval of 1 year. In addition
a further 3 patients died before the end of the interval period.
Sixteen patients had complete or near complete data sets at
interval testing.
Twenty two age- and education- matched controls were
recruited from the panel of volunteers at the MRC Cognition
and Brain Sciences Unit (CBU) or from spouses of patients.
Controls had normal hearing and corrected vision and did not
have significant neurological or psychiatric comorbidity.
Motor and cognitive testing
Motor function was assessed with section III of the Unified
Parkinson’s Disease Rating Scale (UPDRS) [9] and the PSP
rating scale (PSPRS) [5]. The PSPRS also includes sections
for bulbar, oculomotor and personality changes. Scores for
UPDRS and PSPRS were transformed by simple inversion so
that high scores represented better function for ease of
comparison across all tests. This was achieved by subtracting
participant scores from the maximal test score (108 for
UPDRS, 100 for the PSPRS total score and 5 for the PSPRS
stage subscore).
Cognitive testing used the Addenbrooke’s Cognitive
Examination – revised (ACE-R) [10], the Frontal Assessment
Battery (FAB) [11], the cubes subsection of the Visual Object
and Space Perception Battery (VOSP) [12], the Hayling test
and Brixton test [13]. There is a timed component in the
Hayling test. Given the bradyphrenia and bradykinesia evident
in PSP, we used only the number of incorrect responses in the
second section of the test, assessing unsuccessful inhibition by
participants, without reference to timing of responses. Hayling
A errors refers to participants choosing, incorrectly, a
stereotyped ending for a sentence. Hayling B errors are
answers, which although semantically related, are not
stereotyped. Scores for correct answers were given so that
higher scores represented better function.
Saccadometry
Saccadometry was completed at baseline and interval.
Saccades were measured using a head mounted binocular
infra red sclerometer, recorded at 1kHz and low pass filtered at
250Hz, with 12 bit resolution [14]. It presents targets for the
participants using low powered lasers mounted on the front and
angled at +10°, 0 and -10° azimuth. The saccadometer uses a
step task paradigm. After a random initial period between 0.5
and 1.0 seconds the central target is extinguished and
simultaneously either the left or right target presented. The
device measures the latency of the resulting saccade (time
between the target moving and eyes starting to move). The
device was automatically calibrated using a short series of
presentations of the targets at the beginning of the session.
Participants sat at a distance of 1.5 metres from a blank wall
with the room darkened. Because the stimuli move exactly with
the head, a bite bar is not required, leading to increased
subject comfort.
After testing, the data were downloaded to a laptop and pre-
processed using Latency Meter v 2.10 [14]. This contains an
automated validation program that compares the log likelihood
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value for the position and velocity traces for each trial to the
mean and standard deviation values for all the trials in the
session. This is used to reject blinks, saccades in the wrong
direction, and grossly abnormal traces using a rejection
threshold for either the velocity or position traces. Saccade
data were then analysed using SPIC software employing the
Table 1. Summary of studies giving data concerning the onset or progression of clinical aspects of PSP.
  Motor Oculomotor Cog   Bulbar
  b/kin falls w/chair other VSNGP other    d/arthria unintel d/phagia
sev d/
phagia
Brusa et al.[40] P     50% @ 2-4       
Golbe et al.[41]a R   8.2 +  +  3.4  4.4  
Pillon et al.[26]b P       +     
Collins et al.[42] R  0.7 (0-3)   1.5 (0.5-2.5)       
Litvan et al.[24]c R 88% [1]96% [2]
83% [1]
100% [2]   
79% [1]83%
[2]  +
75% [1]
100% [2]  
16% [1] 83%
[2]  
Santacruz et al.[27]d P 4.6-5.6 2.6-3.6 5.6-6.6   + + 2.6-3.6 5.6-6.6 3.6-4.6  
Muller et al.[30] R        2  3.5  
Carrilho et al.[43]e M     +2.5 (0-5)   +1 (1–3)  +1(1-3)  
Nath et al. [32] R  0 (0-16)      1.75 (0-15)  3.6(0-16) 5 (0.6-17)
Goetz et al.[44] R   4.8 (3.8-7.6)      5.9(4-8.3)   
Macia et al.[25]f M  0.6 Daily 3.1   2.5+/-1 + + 2 3.8 2.9 4.6
Golbe et al.[5]g P   4.8-5.8 +        
Donker Kaat et al.
[21] P     3.9 (0-14)       
O’Sullivan et al.[45]h R  3.9+/-2.5 6.4+/-2.7    +  6+/-2.5  6.4+/-2.4
Bensimon et al.[7]i P    +        
Payan et al.[6]j P    +  + +     
Whitwell et al.[4]k P    +        
Median time between disease onset and feature onset in years. Range is given in curved parentheses, standard deviation as +/-. P, R or M in the second column is
prospective, retrospective or mixed prospective and retrospective studies respectively. A + in a column refers to the footnotes giving additional data or rates of progression.
b/kin is bradykinesia, w/chair is when patients require a wheelchair, VSNGP is vertical supranuclear gaze palsy, d/arthria is dysarthria, unintel is unintelligible, d/phagia is
dysphagia, sev d/phagia is severe dysphagia, cog is cognitive symptoms.
a Gait difficulty was seen at 0.3 years and use of a walking aid at 3.1 years. Patients had visual symptoms at 3.9 years.
b Neuropsychological diagnosis of dementia increased from 37.5% to 70% of patients in 15.3 months.
c Frontal symptoms were noted in 46% [1] and 58% [2]. [1] refers to first visit and [2] to last visit. Mean time between visits was 2.2 years (+/- 1 year).
d Time to not being able to read 2.6-3.6 years, word finding difficulties 3.6-4.6 years and memory problems 5.6-6.6 years. Times given are for 50% of patients to have the
given level of difficulty or worse. First visit was at 2.6 years.
e Times given here are times from diagnosis and marked with a +.
f Figures refer to falls occurring at all or on a daily basis; some dysphagia and choking at each meal; blurred vision (1.2 years) and being unable to read (2.9 years).
Cognitive difficulties were noted in 40% in the first two years and 88% in more advanced stages (mean 4.5 years).
g Time given is the time from onset until less than 50% of patients with a baseline score of 40-49 retain some useful gait (PSPRS question 26 score < 4). Overall mean
progression of PSPRS was 11.3 points per year.
h Falls refers to more than 2 falls in a year. Cognitive impairment occurred at 4.2 years +/-2.9 (ADL impairment due to cognition deficits).
i Short Motor Disability Scale 3.1+/-4.4, Schwab and England Activities of Daily Living - 16.3+/-17.5, Hoehn and Yahr 0.5+/-0.8, Clinical global impression of Disease severity
0.7+/-0.7. Figures given are mean points changed per year +/- standard deviation.
j The NNIPPS- Parkinson plus scale is a composite scale consisting of among others, motor, ocular and mental features designed for use in multi-system atrophy and PSP.
This showed a total rate of change of 25.8 points per year. Motor ability and bradykinesia changed at 4.0-4.6 points per year, oculomotor ability at 2.2 points per year, bulbar
function at 3.2 points per year, mental function at 2.1 points per year and urinary function at 1.0 points per year.
k Annual change in the PSPRS for those diagnosed initially with only probable PSP was 18 points a year.
doi: 10.1371/journal.pone.0074486.t001
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LATER (Linear Approach to Threshold with Ergodic Rate)
model [15–17] and reciprobit plots of response latencies.
A typical reciprobit plot of a series of latencies is shown in
Figure 1. The majority of the saccade population adhere to a
normal distribution of inverse latencies, and can be seen to lie
along a straight line in the reciprobit plot. There are a minority
of saccades that are generated differently, with a distinct
normal distribution of inverse latencies with high variance.
These are seen with a reduced latency and lie along a different
line – the ‘early’ saccade distribution. Three parameters, the
reciprocal of the median latency, mu, and the slopes of the
early and main lines, early sigma and sigma respectively, are
sufficient to describe the two inverse latency distributions and
can be related directly to the physiology of visually evoked
saccade generation [17]; these parameters are estimated from
the observed distributions by minimisation of the Kolmogorov-
Smirnov one-sample statistic.
Statistical analysis
Statistical analysis used SPSS v 15 (SPSS Inc., Chicago,
IL). Parametric data for patients and controls were compared
with t-tests, one way (ANOVA) or repeated measures ANOVA
(rm-ANOVA) with post hoc contrasts. Baseline and interval
parametric data for patients were compared with paired t-tests.
Non-parametric data were investigated with Mann Whitney or
Kruskal Wallis. χ2 tests were used for categorical data.
Where the rate of change for different tests were compared,
the annualised normalised score was used. This is the
difference in scores for each test divided by the time interval
between tests and multiplied by 1 year. This score was then
divided by the maximum score for the test in order to compare
different tests. For saccadometry, mu was divided by the mean
plus two standard deviations for the controls (6.38).
Power calculations used Gpower 3.1.5 [18,19] with an alpha
value of 0.05, Beta value of 0.2 (power 80%) and two sided t
tests. Sample sizes were estimated for interventions that
reduced the rate of decline by 25% and 50%.
Results
The groups were well matched demographically at baseline
(see table 2). Figures 2-4 show baseline test scores for
controls and all patients. It can be seen that patients were
significantly worse than controls at baseline for all tests (see
also table 3). Repeat testing of the patients followed up were
completed at a mean interval of 1.2 years (SE 0.07).
Figures 2-4 and tables 4-6 show the annualised change in
test score for those patients who completed both baseline and
Figure 1.  Reciprobit plot of saccade latencies from a healthy volunteer.  Cumulative probability is plotted on the y axis on a
probit scale. Using this scale, plotting a normal distribution results in a straight line. Latency is plotted on the x axis using a
reciprocal scale. The reciprocals of the latencies are equally spaced along this scale. Additionally this scale is mirrored, so that short
latencies are to the left and long to the right: infinite latencies, whose reciprocals are zero, therefore form the right hand margin.
Because their reciprocal latencies are normally distributed, with mean mu and standard deviation sigma, most latencies lie on a
straight line (red), the main distribution, whose median and slope correspond to mu and sigma. In addition, under some conditions
there may be a sub-population of early saccades (blue) that lie on a line of shallower slope, corresponding to a third parameter early
sigma.
doi: 10.1371/journal.pone.0074486.g001
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interval testing after a year with the paired t test comparison. It
can be seen that for the majority of the tests, the mean change
in score was either zero or very close to zero. The exceptions
to this were the scores for the PSP Rating Scale (PSPRS)
which showed a mean change over a year of 11.3 points
(t(15)=11.2, p<0.001) (see table 4 and Figure 2), the Unified
Parkinson’s Disease Rating Scale III (UPDRS), which showed
a mean change of 8.3 points (t(15)=3.6, p=0.003) (see table 4
and Figure 2) and mu (the inverse median latency for
saccades), which showed a mean decrease in mu of 0.4
seconds-1(equivalent to an increase in latency of 0.02 seconds)
(t(13)=2.5, p=0.01) (see table 6 and Figure 4).
Although the comparisons between baseline and interval
only included patients for whom we had both baseline and
interval data, we looked for differences between those baseline
patients who could not complete interval testing and those who
could, in case their drop out had caused a bias.
Demographically, there was no difference between these two
patient subgroups in age (t(37)=0.4, p=0.7), gender
(χ2(1)=0.01, p=1.0), education years (U=183, p=1.0) or disease
duration (U=115, p=0.05). The lack of progression of cognition
over a year was surprising, so we also looked at cognitive
differences at baseline between those patients who we could
and couldn’t test at interval. Allowing for Bonferroni corrections
(p<0.01 as significant for 5 comparisons) there were no
differences (FAB (t(19)=1.7, p=0.12), Hayling A (t(21)=0.1,
p=0.9), Hayling B (t(21)=0.9, p=0.4), ACE-R (t(21)=2.4, p=0.03,
Brixton (t(18)=-1.3, p=0.2)).
Figure 5 shows the annualised normalised rate of change of
the UPDRS, PSPRS, mu and the ACE-R. Normalising each
test to its maximum enables comparison directly across tests. It
can be seen that cognitive function as measured by the ACE-R
changes only very slightly over a year whereas the PSPRS
changes markedly. Repeated measures ANOVA for the
normalised annualised rates of change for ACE-R, UPDRS, mu
and PSPRS shows that there was a significant main effect for
rates of change in different domains of the PSP phenotype
(F(3,39)=3.15, p=0.036). Post hoc contrasts revealed that rates
of change were significantly more for PSPRS when compared
to ACE-R (F(1,13)=17.2, p=0.001) but not for mu compared to
PSPRS (F(1,13)=3.4, p=0.09) or for ACE-R compared to
UPDRS (F(1,13)=3.9, p=0.7).
Figure 6A shows how each element of the PSPRS changed
over the course of a year, ordered from most change to the
least. Figure 6B shows the subsection scores of the PSPRS
ordered by most change. As can be seen in Figure 6, the gait/
midline sections of the scale undergo the most change,
followed by changes expressed in the history given by the
carer and patient.
We extended the analyses to investigate the potential role of
the tests used in this study in therapeutic trials. The change in
test scores over an interval of a year was used to calculate an
effect size for power calculations. Table 7 shows the estimated
group sizes needed to reveal a putative reduction of 25 and
50% in the rate of decline on each of the principal measures,
over 12 months.
In addition, we investigated the correlation between baseline
test scores and disease duration. Examining the patients for
whom we had both baseline and interval data, there was a
significant correlation between PSPRS and disease duration
(Pearson correlation 0.68, p (2 tailed) = 0.005), with none of the
other 11 measures tested having a p value of less than 0.1.
Table 2. Demographics and baseline scores for healthy controls and patients.
Group N Fem   AGE EY DD O–D UPDRS PSPRS Br FAB HayA HayB ACE VOSP Mu Sigm
PSP
Baseline 23 39
71.1
(8.6)
11.0
(9.0-19.0)
3.0
(1.3-17.3) 2.2 (0.7-17)
33.8
(15.7)
45.0
(19.7)
3.1
(2.0)
10.8
(3.9)
3.0
(2.8)
2.3
(2.0)
76.4
(10.9)
7.6
(3.2)
4.0
(1.1)
1.3
(0.5)
PSP
Interval 16 40
68.6
(7.5)
11.0
(10.0-19.0)
4.0
(2.6-12.2)
2.2
(0.7-10.5)
28.4
(12.1)
43.3
(19.0)
2.8
(1.8)
11.7
(3.6)
3.0
(3.1)
2.5
(2.3)
79.7
(10.1)
8.9
(1.7)
4.3
(0.9)
1.4
(0.5)
PSP
Deceased 4 50
72.3
(5.0) 10.5 (9-14)
4.6
(3.2-9.7) 2.5 (1.1-9.7)
56.5
(12.5)
63.7
(13.3)
3.7
(3.1)
7.8
(4.5)
4.0
(1.8)
1.8
(0.5)
69.3
(7.8)
5.5
(3.5)
3.0
(1.5)
1.2
(0.4)
PSP Unable 3 33 83(9.0) 14 (9-19) 3 (1.8-17.3)
2.0
(1.0-17.0)
31.5
(0.7)
30.5
(21.9) 6.0
10.5
(3.5)
1.3
(1.5)
1.7
(1.2)
68.7
(12.7)
3.7
(5.5) ---- ----
Controls 22 32 71.4(7.6)
13.0
(9.0-20.0) N/A N/A 1 (1.5)
1.3
(1.5)
4.7
(2.3)
16.9
(1.1)
1.0
(1.6)
2.2
(2.3)
93.4
(3.5)
10.0
(0)
4.7
(0.8)
1.0
(0.2)
The groups consist of controls, all patients who were tested at baseline (PSP Baseline), baseline scores for those who were tested at both baseline and interval (PSP
Interval), and baseline scores for those patients who were tested at baseline but either were unable to complete interval assessments (PSP Unable) or died before the
interval assessments were due to be carried out (PSP Deceased). StD: standard deviation. N: number in the group, Fem refers to the percentage of females in the group, Br
is Brixton test scaled score (there is no standard deviation given for “PSP unable” as there was only one patient score in this category), DD is the median symptomatic
disease duration in years, EY is median education years, AGE is mean age, O–D is median time between onset and diagnosis in years, UPDRS is the unified Parkinson’s
disease rating scale, PSPRS is the PSP rating scale, FAB is the frontal assessment battery, ACE-R is the Addenbrooke’s Cognitive Examination Revised, VOSP refers to
the cubes subsection of the Visual Object and Space Perception battery, mu is the mean of the reciprocals of the median latency as measured by saccadometry and sigma
is the mean of the variance of the saccade latencies. There are no values given for mu and sigma in “PSP unable” as the patients were unable to do the test at baseline.
Hayling A refers to the number of category A errors in the Hayling test, and Hayling B to the number of category B errors. The scores for UPDRS, PSPRS, Hayling A and
Hayling B are given untransformed, therefore a higher score indicates deteriorating function. All figures in parentheses are standard deviations except for those for EY, DD
and O–D which are ranges.
doi: 10.1371/journal.pone.0074486.t002
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Figure 2.  Baseline scores and annualised rates of change for motor tests.  Row A shows baseline scores on each test. In
order that all graphs show decline as lower values, the scores have been transformed by subtracting the participants’ score from the
maximum for the test (see methods). Blue diamonds are controls, red squares are patients with PSP. Black triangles mark the
baseline score for patients who could not complete interval testing. Row B shows the difference in score between baseline and
interval, in those patients who completed both assessments. The score has been adjusted so that it shows the change in score over
twelve months Negative values represent worsening of function. In both sets of graphs, the x axis represents a nominal value. In
line A the x axis is arranged so that controls are on the left, patients who completed interval assessments are in the middle and
patients who did not complete the interval assessment are on the right. In line B the scores are arranged randomly. Tests are
named at the top of each column. UPDRS is the Unified Parkinson’s Disease Rating Scale motor sub scale; PSPRS is the PSP
rating scale and PSPRS stage is the stage sub score of the PSPRS. All tests are marked “–inv” to signify that the scale for these
tests has been inverted representing deficit from normal.
doi: 10.1371/journal.pone.0074486.g002
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Using all patients tested at baseline, PSPRS trended to a
correlation (Pearson correlation 0.428, p=0.06). When we
looked at correlations between annualised rate of change and
disease duration, only 2 measures had a significance with
p<0.1: Sigma (Pearson correlation 0.64, p=0.008) and PSPRS
which trended to significance with Pearson correlation 0.449,
p=0.081. However, none of these were significant if Bonferroni
corrections were used (p<0.004).
Discussion
This study examined the longitudinal change in progressive
supranuclear palsy, including the cognitive, motor and
oculomotor dimensions of this complex disease. Over one
year, motor functions, and oculomotor decision time (saccade
latency) changed significantly. However, multiple cognitive
measures did not change significantly, despite being
profoundly affected by the presence of disease at baseline.
The test exhibiting the greatest annual change was the PSP
rating scale (see Figure 5) [5]. Other studies have also shown a
comparable change in this composite score [4–6]. Golbe et al.
Figure 3.  Baseline scores and annualised rates of change for cognitive tests.  Tests are named at the top of each column.
FAB is the Frontal Assessment battery; Hayling A-inv is the number of correct category A answers in the Hayling test; Hayling B-inv
is the number of correct category B answers on the Hayling test; ACE-R is the Addenbrookes Cognitive Examination - Revised.
Row A shows baseline scores on the test. Blue diamonds are controls, red squares are patients and black triangles mark the
baseline score for patients who could not complete the interval testing. Hayling A and Hayling B scores have been transformed so
that a higher score represents a better function (see methods). Row B shows the difference in score between baseline and interval,
in those patients who completed both assessments. The score has been adjusted so that it shows the change in score over twelve
months. Negative values represent worsening of function. In both sets of graphs, the x axis represents a nominal value. In line A the
x axis is arranged so that controls are on the left, patients who completed interval assessments are in the middle and patients who
did not complete the interval assessment are on the right. In line B the scores are arranged randomly.
doi: 10.1371/journal.pone.0074486.g003
Longitudinal Assessment of PSP
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Figure 4.  Baseline scores and annualised rates of change for visual and oculomotor tests.  Tests are named at the top of
each column. VOSP is the Visual Object and Space Perception battery and mu is the reciprocal of the latency as measured by
saccadometry. Row A shows baseline scores on the test. Blue diamonds are controls, red squares are patients and black triangles
mark the baseline score for patients who died before interval testing. A lower value on the y axis for the mu graph corresponds to a
lengthening of latency between stimulus presentation and saccade initiation. Row B shows the difference in score between baseline
and interval, in those patients who completed both assessments. The score has been adjusted so that it shows the change in score
over twelve months, irrespective of how far apart the assessments were. Negative values represent worsening of function. In both
sets of graphs, the x axis represents a nominal value. In line A the x axis is arranged so that controls are on the left, patients who
completed interval assessments are in the middle and patients who did not complete the interval assessment are on the right. In line
B the scores are arranged randomly.
doi: 10.1371/journal.pone.0074486.g004
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Table 3. Test comparisons between controls and patients at baseline.
 UPDRS PSPRS PSPRS stage Brixton FAB Hayling A Hayling B ACE-R VOSP Mu Sigma
Control Mean 1 1.3 0 4.7 16.9 1.0 2.2 93.4 10.0 4.7 1.0
Patient Mean 33.8 45.0 3.3 3.1 10.8 3.0 2.3 76.4 7.6 4.0 1.3
t(df) -9.7 (21.4) -10.2 (20.2) -13.7 (20.0) 2.3 (40) 6.8 (22.9) -3.0 (35.7) -0.12 (43) 7.1 (26.8) 3.6 (22) 2.1 (39) -2.5 (24.3)
P value <0.001 <0.001 <0.001 0.02 <0.001 0.005 1.0 <0.001 0.002 0.04 0.02
Mean control and patient baseline scores are given. UPDRS is the unified Parkinson’s disease rating scale, PSPRS is the PSP rating scale, FAB is the frontal assessment
battery, ACE-R is the Addenbrooke’s Cognitive Examination revised, VOSP refers to the cubes subsection of the Visual Object and Space Perception battery, mu is the
mean of the reciprocals of the median latency as measured by saccadometry and sigma is the mean of the variance of the saccade latencies. Hayling A refers to the number
of category A errors in the Hayling test, and Hayling B to the number of category B errors. The scores for UPDRS, PSPRS, Hayling A and Hayling B are given
untransformed, therefore a higher score indicates deteriorating function. t is the t statistic, df is the degrees of freedom, p values given are two tailed. Results have been
corrected where control and patient variance were not equal. This process gives an altered value for degrees of freedom. Using Bonferroni correction with 10 comparisons, a
p value less than p=0.005 would be significant. In that case mu, sigma, Hayling B and Brixton tests would not be significant.
doi: 10.1371/journal.pone.0074486.t003
Figure 5.  Graph showing annualised and normalised rates of change for different aspects of disease.  Green squares are
the change in scores for the Addenbrookes Cognitive Examination Revised, green triangles are rates of change for mu (reciprocal
latency), purple squares are the change in scores for the Unified Parkinson’s Disease Rating Scale (UPDRS) motor subsection and
the purple triangles are the change in scores for the PSP rating scale (PSPRS). The horizontal black lines are the mean rate of
change for each test. Values below the x axis represent worsening of patients’ conditions and those above the x axis are improving.
doi: 10.1371/journal.pone.0074486.g005
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showed an annual change of 11.3 points per year, Payan et al.
8.7 points per year and Whitwell et al. showed a change of 18
points. Whitwell et al. went on to consider the change in
PSPRS and the change in volume of the midbrain, measured
using MRI, as biomarkers for future trials. For 80% power with
a 40% reduction in outcome variable over a year, 36 patients
were estimated to be needed in each treatment arm using
midbrain volume and 45 for total PSPRS score.
One of the most interesting and novel results is that
cognition, despite being very disordered in a significant
proportion of patients, does not change appreciably over the
course of a year (see Table 5 and Figure 3). This stability was
seen in multiple tests, including the ACE-R, Hayling test errors,
Frontal Assessment Battery and Brixton test. The only
exception was the mental sub section of the PSPRS (see
Figure 6). This section of the PSPRS has a measure of
bradyphrenia – a cardinal cognitive feature of PSP – which
Table 4. Baseline and interval scores with paired t tests for
motor tests.
 UPDRS* PSPRS* PSPRS stage
Baseline 28.4 32.8 3.1
Interval 36.7 44.1 3.6
t (df) 3.6 (15) 11.2 (15) 2.2 (15)
p value 0.003 <0.001 0.02
Mean baseline and interval scores are given. UPDRS is the unified Parkinson’s
disease rating scale, PSPRS is the PSP rating scale. The scores for UPDRS,
PSPRS and PSPRS stage are given untransformed, therefore a higher score
indicates deteriorating function. t is the t statistic, df is the degrees of freedom, p
values given are one tailed. P values are reported uncorrected. The p value for
which differences in baseline and interval scores would be significant using the
Bonferroni correction controlling for 3 comparisons is p<0.017. The UPDRS and
PSPRS but not the PSPRS stage are significant at this level (marked with an
asterisk *).
doi: 10.1371/journal.pone.0074486.t004
Table 5. Baseline and interval scores with paired t tests for
cognitive tests.
 Brixton FAB Hayling A Hayling B ACE-R
Baseline 2.8 11.7 12 12.5 79.7
Interval 2.7 11.7 11.9 12.9 76.6
t (df) 0.3 (15) 0.4 (14) 0.08 (15) -0.7 (15) 1.9 (15)
p value 0.8 0.7 0.9 0.2 0.04
Mean baseline and interval scores are given. FAB is the frontal assessment
battery, Hayling A is the number of category A errors in the Hayling test, and
Hayling B the number of category B errors. ACE-R is the Addenbrooke’s Cognitive
Examination Revised. The scores for Hayling A errors and Hayling B errors are
given untransformed, therefore a higher score indicates more errors and therefore
deteriorating function. t is the t statistic, df is the degrees of freedom, p values
given are one tailed. The p value for which differences in baseline and interval
scores would be significant using the Bonferroni correction for 5 comparisons is
p<0.01. None of the cognitive tests are significant at this level.
doi: 10.1371/journal.pone.0074486.t005
deteriorated over one year even though it is not objectively
measured or operationalised.
Cross sectional studies have found no correlation between
cognitive function and disease duration [20–22], supporting our
findings. However, some studies have reported that cognitive
symptoms appear to progress throughout the disease
[1,4,6,23–27]. Only three of these were prospective longitudinal
studies, of which, one used the PSPRS [4] and one used, as in
the PSPRS, a carer reported questionnaire biased towards
apathy, bradyphrenia and depression [6]. The other longitudinal
study [24] found only a 12% increase in frontal lobe
symptomatology between first and last visit (46% to 58%)
compared to larger increases in other features of the disease,
suggesting cognitive impairment had developed early and then
remained relatively stable. Early cognitive impairment is also
suggested by a PET study which found frontal cortical
hypometabolism in patients with mild disease [28]. Taken
together, these data could imply that frontal cognitive
dysfunction occurs before overt presentation of the motor
symptoms that usually lead to diagnosis and then remains
relatively stable, apart from bradyphrenia. New treatments to
avert cognitive impairment in PSP would therefore require a
transformation in the awareness, recognition and specialist
referral pathways for PSP.
Within the PSPRS, it can be seen (Figure 6) that large
changes occur for the gait/midline and history sections. Early
falls are a core inclusion criteria for PSP, while the presence of
a gait/midline disorder is reflected in the supportive criteria [8].
Although progression often leads to wheelchair dependence,
other midline features (neck rigidity for example) appear to
continue to progress. The change in gait/midline problems on
the PSPRS is mirrored in the UPDRS motor section and has
been seen in other studies [4,6].
The change in PSPRS mean score for dysphagia was below
the rate of change of the overall score and that for dysarthria is
only just above the overall score. Several studies have shown
that the leading cause of death in PSP is respiratory
complications arising from aspiration [24,29–31], with
dysarthria also deteriorating during the illness [6,24,25,30,32].
We may have seen greater changes if our patients had been at
Table 6. Baseline and interval scores with paired t tests for
visual and oculomotor assessment tests.
 VOSP Mu* Sigma
Baseline 8.9 4.3 1.4
Interval 8.7 3.9 1.4
t (df) 0.6 (15) 2.5 (13) 0.4(13)
p value 0.3 0.01 0.4
Mean baseline and interval scores are given. VOSP is the Visual Object and
Space Perception battery, mu is the mean of the reciprocals of the median latency
as measured by saccadometry, sigma is the mean of the variance of the saccade
latencies. t is the t statistic, df is the degrees of freedom, p values given are one
tailed. The p value for which differences in baseline and interval scores would be
significant using the Bonferroni correction for 3 comparisons is p<0.017. Only mu
is significant at this level (marked with an asterisk*).
doi: 10.1371/journal.pone.0074486.t006
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Figure 6.  Graph showing the rate of change for individual items (A) and section totals (B) of the PSP rating scale
(PSPRS).  Bars extending to the right of the y axis are those parts of the scale where there has been a worsening of symptoms,
those to the left an improvement of symptoms. The scale on the x axis refers to annualised normalised rates of change. The black
vertical line on Figure A corresponds to the mean change of the overall total of the PSPRS scale.
doi: 10.1371/journal.pone.0074486.g006
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more advanced stages of the illness. However, these findings
may also be due to dysarthria and dysphagia being variable
during the course of the day or non-linearity of the scale,
relying, for example, on the patient coughing once or many
times on drinking water [5].
Oculomotor function changed over one year, including the
range of vertical gaze in the PSPRS (cf [33]). Horizontal gaze
range, in contrast, was stable. However, we were especially
interested in the latency immediately prior to a saccade,
resulting from a cortical and subcortical supranuclear
oculomotor decision network. We identified a small but
significant change in latency (mu, reciprocal latency) between
baseline and interval, indicating an increase in latency for
visually evoked horizontal saccades. Such saccades have
been proposed as a biomarker for the diagnosis or progression
of PSP and other neurodegenerative disorders [34–37],
although other studies have found variable changes in saccade
parameters over time [6,37,38]. We suggest that while the
latency of horizontal saccades remains useful to explore the
neural systems of decision making in disease, and perhaps
long term change in PSP, it is not optimal as a marker of
change over 1 year, the typical timescale for pharmaceutical
trials.
In our study, the greatest change was seen in the PSPRS,
particularly the gait/midline section. We did not assess the
Parkinson’s plus scale developed within the NNIPPS trial (the
Natural history and Neuroprotection in Parkinson Plus
Syndromes, NNIPPS-PPS) [6]. This scale was developed by a
consensus of experts and includes sections similar to parts of
the UPDRS (motor, mental and activities of daily living (ADL)
sections) and the PSPRS (mental section). As in our study, the
greatest annual change was seen in mobility, axial
bradykinesia and rigidity. They also found a large annual
change in limb bradykinesia, whereas our limb section of the
PSPRS was one of the sections that changed least.
Table 7. Sample size estimates for different markers of
PSP progression.
Test d Group size 25% effect Group size 50% effect
PSPRS 1.2 176 45
UPDRS 0.73 486 119
PSPRS stage 0.51 967 243
Mu 0.45 1,242 312
ACE-R 0.27 3,447 863
Brixton 0.07 51,259 >12,000
Hayling A 0.02 627,910 >150,000
FAB 0.01 2,511,637 >620,000
The group size is estimated for each arm of an intervention (not including attrition)
where a therapy reduced progression of that aspect of the disease by 25 or 50%.
Alpha is set at 0.05, beta (β) at 0.2 (ie. a power of 80%). PSPRS is the progressive
supranuclear palsy rating scale, UPDRS the motor section of the unified
Parkinson’s disease rating scale, Mu is the reciprocal of the latency of visually
evoked horizontal saccades, ACE-R is the Addenbrooke’s Cognitive Examination
Revised, Brix is Brixton, Hay A is the number of type A errors in the Hayling test
and FAB is the Frontal Assessment Battery.
By contrasting the range of tests which are abnormal at
baseline in PSP (median time from onset to recruitment 3.0
years) with the tests which change over one year’s interval, it is
clear that motor, oculomotor and cognitive systems evolve at
different timescales. From our data, cognition deteriorates early
in susceptible individuals and then remains relatively stable.
Motor deficits also occur early but continue to progress
throughout the whole course of the disease. Oculomotor
function, in terms of the range of eye movements, deteriorates
before the time of diagnosis but continues to progress slowly
during the middle stage of disease. Oculomotor function in
terms of saccadic latency may be affected by disease, and may
be informative about within-subject differences in cognition or
brain function [36] but does not change markedly at the group
level.
The differential rates of deterioration may be due to the
relatively domain specific cortical – subcortical pathways [39]
having different susceptibilities to PSP pathology or different
capacities for functional compensation. This differential
progression has important implications for patients. However it
is also relevant to disease-modifying drug trials, where it is
critical to choose the best marker of disease progression. We
have used our data to assess the tests used as markers of
disease progression, giving sample sizes needed depending
on the effect size and likely effect of any treatment (table 7). It
should be noted that our calculations pertain to studies of
comparable patients at similar stages of disease (see tables 2
and 3 for our baseline data), and inclusion of early stage
patients may lead to different power calculations. However, we
recruited prospectively from patients who presented to a
regional clinic with a diagnosis of PSP during the time of the
study, it is likely that our cohort is typical of many other centres.
It should also be borne in mind that symptomatic disease
duration is not a good proxy for stage. Although in our sample,
the estimated duration did correlate with baseline PSPRS
score, it did not significantly correlate with rate of change of
PSPRS or other baseline motor and cognitive measures. We
also note that one of our patients had relatively slow
progression, surviving 17 years. This is within diagnostic
criteria and within the range of published cohorts, but
nonetheless unusual.
Using these power calculations, the group sizes vary widely
depending on the different elements of the disease that
investigators may want to influence. Assessing improvement in
cognition would require over 800 patients in each group using
the ACE-R [10] but assessing global function requires a more
tractable 45 patients using the PSPRS [5], which accords with
the estimate from Whitwell et al. [4]. Payan et al. also assessed
the PSPRS and estimated 100 patients in each group would be
needed, but only 40 if using the NNIPPS-PPS [6].
There are several potential limitations to our study. Firstly,
inclusion criteria relied on clinical rather than pathological
diagnosis. However, ten cases have subsequently had a post
mortem examination and the diagnosis of PSP was confirmed
in all ten. Larger trials have also shown a diagnostic accuracy
in excess of 90% [7]. Secondly, our study is relatively small.
However, patients had typical clinical phenotypes of PSP (cf
Richardson’s syndrome, PSP-RS) and completed an intensive
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evaluation across many functional domains over one year,
providing a significant addition to the previous literature on
cognitive, motor or oculomotor progression. PSP usually
progresses quickly and it is possible that those patients who
did not complete interval testing represented those who had a
more aggressive phenotype of the disease, leaving behind a
subset of patients who were less likely to change over a year.
Against this possibility however, is that there was no difference
between survivors and non-survivors in terms of demographics,
cognition or disease duration to suggest that they represented
distinct populations. Furthermore, comparisons between
baseline and interval metrics were only carried out between
patients who had completed both sets of tests.
Another significant limitation is that patients may have
different rates of decline for different functions as the disease
progresses (eg. cognitive vs motor). Furthermore, tests may
vary in their ability to represent the true function of patients
through the course of the illness e.g. due to floor or ceiling
effects. The interpretation and replication of our data, including
power calculations for interventional trials, should therefore
take into account the baseline characteristics of our cohort,
including stage or severity of disease.
In conclusion, we suggest that cognition does not change
appreciably over a year in the middle stages of PSP (after
diagnosis), a novel result that may shed light on the underlying
pathological deterioration in PSP and which needs to be
replicated in further studies. Of clear significance to the
development of new treatments, is that we have shown that
patients show significant deterioration over one year using the
PSPRS severity measure. Indeed, including patients who were
clinically diagnosed with PSP [5], which is broadly equivalent to
the operational diagnostic criteria used by a recent trial [7],
annual change in the PSP rating scale was matched between
our study and the original PSPRS study, at 11.3 points a year
[5]. We also concur with Whitwell et al. that using the PSPRS,
approximately 45 patients in each treatment arm would provide
reasonable power for future clinical trials of a highly effective
treatment (50% slowing of annual decline) [4]. The high rate of
pathological confirmation from the PSP clinical phenotype [7]
and the properties of the PSPRS, support the use of these
simple tools in new clinical trials of this devastating disease.
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